Clinical Trials

New Search
Title   Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial
Disease/Condition   Breast Cancer,Skin Disorders,Oncology (Medical/Hematologic),Neoplasms
Eligibility Criteria   Click here for eligibility requirements
Principal Investigator   Joseph Sparano, MD
Contact Name   Amanda Erakky
Contact Email   aerakky@montefiore.org
IRB/Protocol Number   18-06-369-01
Status   Active/Enrolling
Adult Clinical Trial   Yes
Pediatric Clinical Trial   No
Sub-Specialty   Medical and Hematologic Oncology